SEC Form 4 · accession 0000899243-18-012150
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A Stewart
Officer — President & CEO · Director
Period of report
May 7, 2018
Accepted (ET)
May 9, 2018 · 6:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001723128
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $15.01 | May 7, 2018 | A | 681,199 | A | — | May 7, 2028 | Class A Common Stock | 681,199 | 681,199 | D |
| Restricted Stock UnitsF2,F3 | — | May 7, 2018 | A | 333,111 | A | — | — | Class A Common Stock | 333,111 | 333,111 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on May 07, 2019.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- F3The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.